Available kits and services

Adalimumab is a tumor necrosis factor (TNF) inhibitor that can diminish inflammation. It is a fully human monoclonal antibody. 

Read more about adalimumab.
Contact us to order the level or ADA kit.
To use our drug level and ADA testing services, fill out this form.

Certolizumab binds with high affinity to human TNFα, thereby neutralizing this pro-inflammatory cytokine, which can relieve signs and symptoms in patients with inflammatory conditions. 

Read more about certolizumab.
To use our drug level testing services, fill out this form.

To use our ADA testing services, email us at [email protected]. 

Etanercept competitively inhibits TNF binding to its cell surface receptors, thereby inhibiting the biological activity of TNF.

Read more about etanercept.
To use our drug level testing services, fill out this form.

Golimumab inhibits the inflammatory response by preventing the interaction of TNF-α with its receptors. 

Read more about golimumab.
To use our drug level and ADA testing services, fill out this form.

Infliximab is a tumor necrosis factor (TNF) inhibitor that can diminish inflammation. It is a chimeric human/mouse monoclonal antibody.

Read more about Infliximab.
Contact us to order the level or ADA kit.
To use our drug level and ADA testing services, fill out this form.

Brodalumab is a human monoclonal antibody directed against the pro-inflammatory interleukin 17 receptor (IL17R). Brodalumab is being used in the treatment of moderate to severe psoriasis.

Currently in development, enquire about our fast track assay validation by emailing us at [email protected].

Canakinumab is a human monoclonal antibody directed against interleukin 1 beta (IL1B). Canakinumab is being used in the treatment of of cryopyrin-associated periodic syndromes (CAPS).

Currently in development, enquire about our fast track assay validation by emailing us at [email protected].

Dupilumab is a human monoclonal antibody directed against interleukin 4 receptor alpha (IL4RA). Dupilumab is being used in the treatment of moderate-to-severe atopic dermatitis and for asthma.

To use our drug level testing services, fill out this form.

Guselkumab is a human monoclonal antibody directed against interleukin 23 (IL23). Guselkumab is being used in the treatment of plaque psoriasis.

Enquire about our soon validated drug level assay at [email protected].

Ixekizumab is a humanized monoclonal antibody directed against the pro-inflammatory interleukin 17 alpha (IL17A). Ixekizumab is being used in the treatment of plaque psoriasis and psoriatic arthritis.

Currently in development, enquire about our fast track assay validation by emailing us at [email protected].

Mepolizumab is a humanized monoclonal antibody directed against interleukin 5 (IL5). Mepolizumab is being used in the treatment of severe refractory (eosinophilic) asthma.

Currently in development, enquire about our fast track assay validation by emailing us at [email protected].

Reslizumab is a humanized monoclonal antibody directed against interleukin 5 (IL5). Reslizumab is being used in the treatment of severe (eosinophilic) asthma.

Currently in development, enquire about our fast track assay validation by emailing us at [email protected].

Secukinumab is a human monoclonal antibody directed against the pro-inflammatory interleukin 17 alpha (IL17A). Secukinumab is being used in the treatment of multiple autoimmune diseases.

What can Sanquin do for you?

• Measure drug levels of free drug in the serum using an validated ELISA.
• Measure the immunogenicity of secukinumab.
• Provide assay reagents or co-develop novel testing strategies.
• Folllowing ISO, FDA/EMA, RUO guidelines.

Enquire about our validated drug level and ADA assays by emailing us at [email protected]. 

Reference levels

In general, reference levels are not provided in the drug insert. 

Reference levels established using the Sanquin assay

PSORT publication coming up shortly.

Reference levels from the general literature

Not available.

Other publications using the Sanquin assay

For an extensive overview of our publications and collaborations, see literature.

Secukinumab background information

Secukinumab is a human monoclonal antibody that targets IL-17A cytokine to downregulate inflammation in psoriasis, an autoimmune dermatological disease. The pathophysiology of psoriasis has not been fully established; however, it is known that dysregulation of innate and adaptive immune responses plays part in the chronic inflammation associated with the disease. IL-17 represents is a six-membered family (IL-17A to F) of pleiotropic pro-inflammatory cytokines, expression of which is found to be elevated in psoriatic skin. These cytokines act on many different cell types and provide defence against different extracellular pathogens causing fungal or bacterial infections. IL-17 cytokines are produced by many cells involved in immune system defence, such as Th17, mast cells, neutrophils, and dendritic cells - all implicated in promoting inflammation. There is evidence linking IL-17 to pathogenesis of multiple autoimmune diseases including rheumatoid arthritis, spondylarthritis, psoriasis, Crohn's disease, multiple sclerosis, and even atherosclerosis.

Biosimilars

Currently, there are no biosimilars for secukinumab available on the market. 

Clinical use

In Europe, Secukinumab is indicvated for the treatment of:

• Moderate to severe plaque psoriasis
• Psoriatic arthritis
• Axial spondyloarthritis
• Two types of juvenile idiopathic arthritis, enthestitis-related arthritis and juvenile psoriatic arthritis

Consult CHMP for details. 

Tocilizumab is a humanised IgG1 monoclonal antibody directed against the receptor of the human pro-inflammatory cytokine IL-6.

Read more about tocilizumab.
To use our drug level and ADA testing services, fill out this form.

Ustekinumab is a fully human IgG1κ monoclonal antibody that targets both interleukin-12 and interleukin-23.

Read more about ustekinumab.
To use our drug level and ADA testing services, fill out this form.

Abatacept modulates a key costimulatory signal required for full activation of T lymphocytes expressing CD28, thereby dampening T lymphocyte-dependent antibody responses and inflammation.

Read more about abatacept.
To use our drug level testing services, fill out this form.

Alemtuzumab is a humanized monoclonal antibody directed against CD52. Alemtuzumab is being used in the treatment of CD52 expressing tumours and relapsing remitting form of multiple sclerosis.

Currently in development, enquire about our fast track assay validation by emailing us at [email protected].

Belimumab is a human monoclonal antibody directed against B-lymphocyte stimulator (BLyS, also commonly known as BAFF). Belimumab is being used in the treatment of autoimmune diseases.

Enquire about our soon validated drug level and ADA assays at [email protected].

Daratumumab is a human monoclonal antibody directed against CD38. Daratumumab is being used in the treatment of CD38 expressing tumours.

Currently in development, enquire about our fast track assay validation by emailing us at [email protected].

Ocrelizumab is a humanized monoclonal antibody directed against CD20 present on B‑lymphocytes. Ocrelizumab is used to treat of relapsing forms of multiple sclerosis.

Enquire about our validated drug level and ADA assays by emailing us at [email protected]. 

Rituximab is a monoclonal antibody directed against CD20 protein present on B‑lymphocytes. Rituximab is used to treat various blood cancers and inflammatory conditions.

Read more about rituximab.
To use our drug level and ADA testing services, fill out this form.

Natalizumab inhibits adhesion-molecule via binding to α4β1 integrin, and is thought to prevent migration of inflammatory cells into the brain in multiple sclerosis. 

Read more about natalizumab.
To use our drug level and ADA testing services, fill out this form.

Vedolizumab is a monoclonal antibody directed at α4β7 integrin, that reduces inflammation specifically in the gut.

Read more about vedolizumab.
To use our drug level and ADA testing services, fill out this form.

Atezolizumab is a humanized monoclonal antibody directed at human programmed death-ligand 1 (PD-L1), a negative regulator of T-cell activity. Atezolizumab potentiates T-cell responses, including anti-tumour responses.

Currently in development, enquire about our fast track assay validation by emailing us at [email protected].

Avelumab is a human monoclonal antibody directed at human programmed death-ligand 1 (PD-L1), a negative regulator of T-cell activity. Avelumab potentiates T-cell responses, including anti-tumour responses.

Currently in development, enquire about our fast track assay validation by emailing us at [email protected].

Durvalumab is a human monoclonal antibody directed at human programmed death-ligand 1 (PD-L1), a negative regulator of T-cell activity. Durvalumab potentiates T-cell responses, including anti-tumour responses.

Currently in development, enquire about our fast track assay validation by emailing us at [email protected].

Nivolumab is a human monoclonal antibody directed at PD-1 receptor, a negative regulator of T-cell activity. Nivolumab potentiates T-cell responses, including anti-tumour responses.

Read more about nivolumab.

Enquire about our validated drug level and ADA assays by emailing us at [email protected]. 

Pembrolizumab is a humanized monoclonal antibody directed at programmed death-1 (PD-1) receptor, a negative regulator of T-cell activity. Pembrolizumab potentiates T-cell responses, including anti-tumour responses.

Enquire about our validated drug level and ADA assays by emailing us at [email protected]. 

Alirocumab is a human monoclonal antibody directed at proprotein convertase subtilisin kexin type 9 (PCSK9) and has been shown to reduce low-density lipoprotein (LDL) cholesterol levels.

Currently in development, enquire about our fast track assay validation by emailing us at [email protected].

Evolocumab is a human monoclonal antibody directed at proprotein convertase subtilisin kexin type 9 (PCSK9) and has been shown to reduce low-density lipoprotein (LDL) cholesterol levels.

Currently in development, enquire about our fast track assay validation by emailing us at [email protected].

Eculizumab is a humanised monoclonal antibody that targets human C5 complement protein and inhibits the activation of terminal complement. 

Read more about eculizumab.
To use our drug level testing services, email us at [email protected]

Trastuzumab is a recombinant humanised IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2), which is overexpressed in about 20-30% of primary breast cancers.

Read more about trastuzumab.
To use our drug level and ADA testing services, email us at [email protected].

Omalizumab prevents binding of IgE to the high-affinity IgE receptor (FcRI), and thereby reduces the amount of free IgE that is available to trigger the allergic cascade

Read more about omalizumab.

To use our drug level and ADA testing services, email us at [email protected].

Pertuzumab is a human monoclonal antibody directed against  the human epidermal growth factor receptor 2 protein (HER2), a protein found on HER2-positive cancer cells. By attaching to HER2, pertuzumab inhibits HER2 producing signals that cause the cancer cells to grow.

Currently in development, enquire about our fast track assay validation by emailing us at [email protected].